Extended indication Yescarta is indicated for the treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL)
Therapeutic value Possible added value
Total cost 65,400,000.00
Registration phase Registered

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information